RYTM insider trading
HealthcareRHYTHM PHARMACEUTICALS, INC.: insider trade history from SEC Form 4 filings.
About RHYTHM PHARMACEUTICALS, INC.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Company website: rhythmtx.com
RYTM insider activity at a glance
FilingIQ tracks 602 insider transactions for RYTM in filings since Oct 6, 2017. The most recent transaction is dated Sep 14, 2026.
Across the full history, 19 open-market purchases
and 316 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RYTM insider trades is 56.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest RYTM Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding RYTM
Frequently asked
- How many insider trades does FilingIQ track for RYTM?
- FilingIQ tracks 602 Form 4 insider transactions for RYTM (RHYTHM PHARMACEUTICALS, INC.), covering filings from Oct 6, 2017 onwards. 26 of those are dated within the last 90 days.
- Are RYTM insiders net buyers or net sellers?
- Across the full Form 4 history for RYTM, 19 transactions (3%) were open-market purchases and 316 (52%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RYTM insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is RYTM in?
- RHYTHM PHARMACEUTICALS, INC. (RYTM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $6.79B.
Methodology & sources
Every RYTM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.